# Huatai Health Fund

> Huatai Health Fund is a VC fund backing Biotechnology, Health Care and Medical. See 7 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Total investments: 7
- Last investment: Aug 2022
- Lead investor: 14%
- Last updated: Aug 2026

Huatai Health Fund is an investment firm.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 4 | 57% |
| Health Care | 3 | 43% |
| Medical | 2 | 29% |
| Life Science | 2 | 29% |
| Hospital | 1 | 14% |

13 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 2 | 29% |
| Series C | 2 | 29% |
| Seed | 1 | 14% |
| Private Equity | 1 | 14% |
| Venture - Series Unknown | 1 | 14% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| China | 6 | 86% |
| Canada | 1 | 14% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Proton Bio | Proton Bio is mainly engaged in gene and cell therapy CDMO service provider, focusing on the field of gene and cell therapy. | $76.3M | Series B | Aug 19, 2022 | https://www.portonbio.com/ |
| Remegen | RemeGen, Ltd. ("RemeGen") is a biopharmaceutical company in China dedicated to fulfilling unmet medical needs for patients with life-threatening conditions. RemeGen's main focus is research and development, manufacturing and commercialization of novel biologics, most notably monoclonal antibodies (mAb) and antibody-drug conjugates(ADCs). Headquartered in Yantai, Shandong Province, China, RemeGen has labs/offices in Beijing and California. |  | Private Equity | Dec 07, 2019 | https://www.remegen.com/ |
| Anovent Pharmaceutical | Anovent Pharmaceutical develops high-quality, safe, and affordable inhalation medicines for hospitals and medical institutions. |  | Venture - Series Unknown | Nov 12, 2019 | http://anovent.com |
| Vazyme Biotech | Vazyme Biotech is devoted to the development and production of enzymes and antibodies. Our products cover clinical diagnosis, molecular diagnostics, high-throughput sequencing and life science research and other related fields. The company is located in the city of Nanjing, china's ancient capital of the Six Dynasties. Vazyme Biotech is in thefront of scenic Qixia mountain, dependent on the regional radiation force of the National Economic and Technological Development Zone of Nanjing. With advanced capability of R&D and cutting- edge technology, Vazyme Biotech will create a new pattern of National Biotechnology. |  | Series B | Apr 01, 2019 | http://www.vazymebiotech.com/ |
| NeoTrident | NeoTrident is a leading provider of scientific innovation lifecycle management software. |  | Seed | May 29, 2018 | http://www.neotrident.com/ |
| CMLabs | The Chain Medical Labs is a professional independent medical laboratory established from a team of experienced technical and management experts which is one of the Shanghai Chain medical investment management Inc. also alliance with few internationally renowned lab and vendors. The company utilize advanced testing methods, quality managementsystems, automation technology as Europe, America and Japan for their Clinical Diagnostics. CMLabs features in clinical laboratory services, clinical trial services, research services, and laboratory information system services to support all medical institutions, as well as assist to obtain ISO15189 certification, CAP accreditation (United States Association of pathology quality system), SOP process and external audit services. | $15.9M | Series C | Apr 23, 2018 | http://www.cmlabs.com.cn/ |
| Geneseeq | Established in 2008, Geneseeq is an industry leader in Next-Generation Sequencing (NGS) fully committed to the research and clinical translation of NGS Genetic Sequencing in the field of personalized medicine. Geneseeq’s world-leading laboratories have successfully passed China’s National Center of Clinical Laboratories(NCCL) External QualityAssessment(EQA), College of American Pathologists(CAP) PT, European Molecular Genetics Quality Network(EMQN) PT, and received 3rd party medical laboratory and clinical PCR amplification laboratory qualifications. |  | Series C | Jul 20, 2017 | https://na.geneseeq.com |

7 of 7 investments shown.

## Co-investors
- [C-Bridge Capital](https://shizune.co/investors/profile/c-bridge-capital) — VC Fund, 2 deals together
- [Advanced Manufacturing Industry Investment Fund](https://shizune.co/investors/profile/advanced-manufacturing-industry-investment-fund) — VC Fund, 1 deal together
- [Boyuanhongsheng](https://shizune.co/investors/profile/boyuanhongsheng) — VC Fund, 1 deal together
- [China Merchants Venture Capital](https://shizune.co/investors/profile/china-merchants-capital) — VC Fund, 1 deal together
- [China Merchants Securities](https://shizune.co/investors/profile/china-merchants-securities) — VC Fund, 1 deal together
- [Cowin Capital](https://shizune.co/investors/profile/cowin-capital) — VC Fund, 1 deal together

## Similar investors

### Similar industry
- [Accel](https://shizune.co/investors/profile/accel) — VC Fund
- [SV Angel](https://shizune.co/investors/profile/sv-angel) — VC Fund
- [Andreessen Horowitz](https://shizune.co/investors/profile/andreessen-horowitz) — VC Fund

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

### Similar country
- [IDG Capital](https://shizune.co/investors/profile/idg-capital-partners) — VC Fund
- [Qiming Venture Partners](https://shizune.co/investors/profile/qiming-venture-partners) — VC Fund
- [HSG](https://shizune.co/investors/profile/sequoia-capital-china) — VC Fund

## Featured in investor lists
- [Enterprise Software Investors in China](https://shizune.co/investors/enterprise-software-investors-china)

## FAQ

### What does Huatai Health Fund invest in?

Huatai Health Fund invests primarily in Biotechnology, Health Care and Medical startups, most often at Series B and Series C stage. Most of the 7 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Huatai Health Fund last invest?

The most recent investment recorded for Huatai Health Fund closed in Aug 2022. Shizune tracks 7 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co